Mozi-q Tablet, Chewable
NDC Package 53590-100-60
Package Information
Mozi-q (ledum palustre twig, urtica urens, simaba cedron seed, delphinium staphisagria seed, grindelia hirsutula flowering top) tablets is adults chew 1 tablet daily, or every 2-3 hours before going outside or when bug bites are present, up to a maximum of 8 tablets daily, or as directed by a health care practitioner. This formulation utilizes a tablet, chewable delivery system. Marketed by Xerion Dispensary Ltd., this product is identified by NDC 53590-100.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53590 - Xerion Dispensary Ltd.
- 53590-100 - Mozi-q
- 53590-100-60 - 60 TABLET, CHEWABLE in 1 BOX
- 53590-100 - Mozi-q
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (53590-100). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53590-100-60 identifies a specific commercial package of 60 tablet, chewable in 1 box of Mozi-q, a human over the counter drug labeled by Xerion Dispensary Ltd.. This tablet, chewable is formulated for oral use and contains delphinium staphisagria seed; grindelia hirsutula flowering top; ledum palustre twig; simaba cedron seed; urtica urens as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Xerion Dispensary Ltd. on October 15, 2012. The current certification is valid through December 31, 2026.
How is this Xerion Dispensary Ltd. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53590010060. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.